Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Current Report · Items 5.02, 9.01 · 8-K

SELLAS Life Sciences Group, Inc.

SLSNASDAQEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) Compensatory Arrangements of Certain Officers On June 24, 2026, SELLAS Life Sciences Group, Inc.…

Filed Jun 25, 2026Accepted Jun 25, 2026, 8:30 AM EDTCIK 1390478Accession 0001104659-26-077556
Share

Company context

Life Sciences Group, Inc. SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please visit www.sellaslifesciences.com

Current securities

Recent company filings

  1. Results of Operations and Financial ConditionAug 11, 2026
  2. 10-Q filingAug 11, 2026
  3. SCHEDULE 13G filingJul 31, 2026
  4. Results of Operations and Financial Condition · Other EventsJul 27, 2026
  5. Submission of Matters to a Vote of Security HoldersJun 18, 2026

Disclosure sections

Items 5.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) Compensatory Arrangements of Certain Officers On June 24, 2026, SELLAS Life Sciences Group, Inc. (the “Company”) entered into (i) an amendment (the “Stergiou Amendment”) to that certain employment agreement effective as of July 1, 2019 (the “Stergiou Employment Agreement”), by and between the Company and Dr. Angelos Stergiou, the Company’s President and Chief Executive Officer, (ii) an amended and restated severance and change of control letter agreement with John Burns, the Company’s Senior Vice President and Chief Financial Officer (the “Burns Agreement”), and (iii) an amended and restated severance and change of control letter agreement with Dr. Dragan Cicic, the Company’s Senior Vice President and Chief Development Officer (the “Cicic Agreement” and collectively with the Stergiou Amendment and the Burns Agreement, the “Agreements”). The Agreements were approved by the Board of Directors (the “Board”) of the Company, upon recommendation of the Compensation Committee of the Board, following a review with the Company’s independent compensation consulting firm of certain market and competitive practices relating to executive severance agreements. Amendment to Stergiou Employment Agreement The Stergiou Amendment amends the Stergiou Employment Agreement to provide that certain payments made to Dr. Stergiou as part of his change in control severance benefits will be paid in a lump sum payment. The terms of the Stergiou Employment Agreement remain unchanged in all other respects. Amended and Restated Severance and Change of Control Letter Agreements with John Burns and Dragan Cicic The Burns Agreement and the Cicic Agreement each amend and restate in their entirety the prior change of control severance agreements and non-change of control severance benefits applicable to Mr. Burns and Dr. Cicic, respectively. Under the Burns Agreement and the Cicic Agreement, if Mr. Burns or Dr. Cicic, as applicable, is terminated by the Company without Cause or resigns for Good Reason, and such termination does not occur within the Change of Control Period (as defined below), the executive will be entitled to receive the following severance payments and benefits: (i) continuing severance pay equal to his then-current base salary for a period of nine months, payable in accordance with the Company’s normal payroll practices; (ii) a pro rata portion of his target bonus for the year of termination, payable in installments over the nine-month severance period; and (iii) reimbursement of COBRA premiums for continued participation in the Company’s medical and dental benefit plans for up to nine months following termination (or until the executive becomes eligible for coverage under another employer’s group health plan, if earlier). Under the Burns Agreement and the Cicic Agreement, if Mr. Burns or Dr. Cicic, as applicable, is terminated by the Company (or its successor) without Cause or resigns for Good Reason within one month prior to, or one year following, a Change of Control (such period, the “Change of Control Period”), the executive will be entitled to receive the following severance payments and benefits: (i) a lump sum payment equal to 15 months of his then-current base salary; (ii) a lump sum payment equal to his target bonus for the year of termination; (iii) reimbursement of COBRA premiums for continued participation in the Company’s medical and dental benefit plans for up to 18 months following termination (or until the executive becomes eligible for coverage under another employer’s group health plan, if earlier); and (iv) immediate vesting in full of all then-unvested equity awards held by the executive as of the date of termination. Receipt of the severance payments and benefits is conditioned upon the effectiveness of a separation and general release agreement in a form to be provided by the Company. The foregoing descriptions of the Agreements do not purport to be complete and are qualified by reference to the full text of the Stergiou Amendment, the Burns Agreement and the Cicic Agreement, copies of which are attached hereto as Exhibits 10.1, 10.2 and 10.3, respectively, and incorporated herein by reference.